Skip to content
★ Sign in to follow
원텍 logo

원텍 Stock: price and insider trades · South Korea

No insider purchase over the last 90 days. The latest, by 김정현, was filed 06 May 2026.

원텍: what insiders have been doing

원텍, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). Between 2 November 2025 and 2 November 2026, 6 insiders published 11 filings.

On the market, 6 insiders bought (10 purchases totalling €3.3M) while 1 insider sold (1 sale totalling €85k). The totals exclude 1 filing filed without an amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Among those who bought: 3 senior executives, 2 chief executives and 1 board member. One trade stands out by size: a purchase of €1.3M from 김종원, disclosed on 10 April 2026, or 0.44% of market capitalisation.

The data flag 8 purchases as part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. The last insider purchase was made public on 6 May 2026, 188 days ago. The median gap between trade and publication is zero days: most filings appear on the same day. This delay matters because a trade only becomes useful information once it is public.

Compared with its exchange (2,655 companies, median 7 filings), a count of 11 filings is above the norm. Over the whole record (from 2021), the tally stands at 38 purchases and 6 sales.

In the same sector, recent insider purchases at Dynavox Group AB and UCB also feature in our signals. Source: insider filings from DART (FSS). Past trades are no guide to future returns.

Insider Decl.
84
Thresholds
n/a
Buy Volume
€12M
38 ops. · all time
Sell Volume
€14M
6 ops. · all time

Who traded when

BuySale
김종원6 buys2 sales
김정현2 buys
김태봉2 buys
서영석2 buys
김창영1 buy
최정윤1 buy

Since the insiders bought

  • Filed 06 May 2026 · 188 days ago · €578k
    -46.7%
    Entry 7,030.00 · Close 30 Oct 2026 3,750.00
  • Filed 17 Apr 2026 · 207 days ago · €387k
    -50.6%
    Entry 7,590.00 · Close 30 Oct 2026 3,750.00
  • Filed 10 Apr 2026 · 214 days ago · €39k
    -49.5%
    Entry 7,420.00 · Close 30 Oct 2026 3,750.00

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Financial data

· cache

Last declaration on 6 May 2026
Declarations84 total
  • ▲
    대표이사 사장Executives
    1B KRW44DART
    130,350 shares@ ₩7,672.000.20% mcap42.8% of flowShareKRXDART:20260506000060
    Canonical exit: 29 Jul 2026 (T+90)
  • ▲
    부원장Executives
    671M KRW37DART
    90,000 shares@ ₩7,460.000.13% mcap80.5% of flowShareKRXDART:20260417000577
    Canonical exit: 13 Jul 2026 (T+90)
  • ▲
    이사Executives
    67M KRW33DART
    10,000 shares@ ₩6,650.000.013% mcap100.0% of flowShareKRXDART:20260410003334
    Canonical exit: 9 Jul 2026 (T+90)
  • ▲
    부사장Executives
    100M KRW37DART
    15,000 shares@ ₩6,650.000.020% mcap100.0% of flowShareKRXDART:20260410003316
    Canonical exit: 9 Jul 2026 (T+90)
  • ▲
    부원장Executives
    161M KRW31DART
    48,635 shares@ ₩3,312.28670.032% mcap19.5% of flowShareKRXDART:20260410003250
    Canonical exit: 9 Jul 2026 (T+90)
  • ▲
    Executives
    €1.3M28DART
    304,928 shares0.44% mcap89.1% of flowKRXDART:20260410003205
    Canonical exit: 9 Jul 2026 (T+90)
  • ▲
    대표이사 사장Executives
    1B KRW46DART
    200,000 shares@ ₩6,650.000.27% mcap57.2% of flowShareKRXDART:20260410003270
    Canonical exit: 9 Jul 2026 (T+90)
  • ▲
    부사장Executives
    100M KRW37DART
    15,000 shares@ ₩6,650.000.020% mcap100.0% of flowShareKRXDART:20260410003393
    Canonical exit: 9 Jul 2026 (T+90)
  • ▲
    대표이사 회장Executives
    118M KRW22DART
    17,226 shares@ ₩6,826.92620.024% mcap4.9% of flowShareKRXDART:20260408001926
    Canonical exit: 27 May 2026 (T+90)
  • ▼
    Executives
    €85k3DART
    21,490 shares0.029% mcap6.0% of flowKRXDART:20260316001023
  • ▲
    대표이사 회장Executives(filed)
    €6,561est.0DART
    1,374 sharesShareKRXDART:20260120000061
    Canonical exit: 20 Apr 2026 (T+90)
  • ▲
    이사Executives(filed)
    €46kest.0DART
    6,822 sharesShareKRXDART:20250908000301
    Canonical exit: 7 Dec 2025 (T+90)
  • ▼
    대량보유자Executives
    €383kest.0DART
    59,950 sharesKRXDART:20250908000287
  • ▲
    대표이사 회장Executives(filed)
    €6,623est.0DART
    1,090 sharesShareKRXDART:20250826000449
    Canonical exit: 24 Nov 2025 (T+90)
  • ▲
    대표이사 회장Executives(filed)
    €6,393est.0DART
    1,255 sharesShareKRXDART:20250430000915
    Canonical exit: 29 Jul 2025 (T+90)
  • ●
    Executives
    Executives(filed)
    0DART
  • ▲
    대표이사 회장Executives(filed)
    €7,007est.0DART
    1,991 sharesShareKRXDART:20250205000058
    Canonical exit: 6 May 2025 (T+90)
  • ▲
    대표이사 회장Executives(filed)
    €10kest.0DART
    3,434 sharesShareKRXDART:20241119000097
    Canonical exit: 17 Feb 2025 (T+90)
  • ▼
    Executives
    €4.8Mest.0DART
    1,001,223 sharesKRXDART:20241007000473
  • ▲
    대표이사 회장Executives
    0DART
    ShareKRXDART:20240731000085
    Canonical exit: 10 Oct 2024 (T+90)
  • ▲
    부회장Executives
    0DART
    ShareKRXDART:20240724000042
    Canonical exit: 20 Oct 2024 (T+90)
  • ▼
    Executives
    €2.7Mest.0DART
    493,178 sharesKRXDART:20240704000105
  • ▼
    Executives
    €4.8Mest.0DART
    861,756 sharesKRXDART:20240702000436
  • ▲
    부사장Executives
    0DART
    ShareKRXDART:20240531001263
    Canonical exit: 27 Aug 2024 (T+90)
  • ▲
    Executives
    €806kest.0DART
    145,129 sharesKRXDART:20240531001236
    Canonical exit: 25 Aug 2024 (T+90)

25 of 84 declarations

About 원텍

원텍 is a company operating in the healthcare and pharmaceutical sector, listed on the XKRX market. It specializes in the development and manufacturing of pharmaceutical and medical products.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations